Cansino Biologics (China) Today
| 688185 Stock | 62.11 5.49 8.12% |
Performance14 of 100
| Odds Of DistressLess than 29
|
Cansino Biologics is trading at 62.11 as of the 25th of November 2024, a 8.12 percent decrease since the beginning of the trading day. The stock's open price was 67.6. Cansino Biologics has about a 29 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. Equity ratings for Cansino Biologics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Cansino Biologics is entity of China. It is traded as Stock on SHG exchange. The company has 114.78 M outstanding shares. More on Cansino Biologics
Moving together with Cansino Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cansino Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cansino Biologics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cansino Biologics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman, CoFounder | Xuefeng Yu | ||||
| Thematic Idea | Soft Drinks (View all Themes) | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Soft Drinks, Health Care, Pharmaceuticals, Drug Manufacturers-Specialty & Generic, Healthcare (View all Sectors) | ||||
Cansino Biologics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Cansino Biologics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsCansino Biologics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cansino Biologics' financial leverage. It provides some insight into what part of Cansino Biologics' total assets is financed by creditors.
| |||||
Cansino Biologics (688185) is traded on Shanghai Stock Exchange in China and employs 1,494 people. Cansino Biologics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 10.45 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cansino Biologics's market, we take the total number of its shares issued and multiply it by Cansino Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cansino Biologics operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 114.78 M outstanding shares.
Cansino Biologics generates negative cash flow from operations
Check Cansino Biologics Probability Of Bankruptcy
Ownership AllocationCansino Biologics holds a total of 114.78 Million outstanding shares. Cansino Biologics shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 62.9 percent of Cansino Biologics outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cansino Ownership Details
Cansino Biologics Risk Profiles
Although Cansino Biologics' alpha and beta are two of the key measurements used to evaluate Cansino Biologics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.27 | |||
| Semi Deviation | 3.76 | |||
| Standard Deviation | 5.2 | |||
| Variance | 27.08 |
Cansino Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cansino Biologics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios |
| All Next | Launch Module |
Cansino Biologics Corporate Management
Elected by the shareholders, the Cansino Biologics' board of directors comprises two types of representatives: Cansino Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cansino. The board's role is to monitor Cansino Biologics' management team and ensure that shareholders' interests are well served. Cansino Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cansino Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yonghui Wu | Vice Marketing | Profile | |
| Jin Cui | Board Secretary | Profile | |
| Xi Luo | Chief Officer | Profile | |
| FCS FCIS | Joint Secretary | Profile |
Other Information on Investing in Cansino Stock
Cansino Biologics financial ratios help investors to determine whether Cansino Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cansino with respect to the benefits of owning Cansino Biologics security.